The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

6 Dec 2013 07:00

RNS Number : 8617U
Sopheon PLC
06 December 2013
 



 FOR IMMEDIATE RELEASE

6 December 2013

 

 

SOPHEON PLC

 

DIRECTORS OPTIONS AND SHAREHOLDING

 

Sopheon plc ("Sopheon" or "the Company") announces that the Company has granted 94,000 options over ordinary shares of 20 pence each in the share capital of the Company ("Ordinary Shares") ("Options") to certain directors. These grants are part of a wider grant of 233,704 Options, to both new and existing staff members. Of this total, 4,000 Options have been granted to new employees.

 

The remaining 229,704 Options have been granted to employees that have been with the Company for five years or longer. This second category represents the replacement of Options previously granted to these employees between 2004 and 2008. As part of this event, the previous Options are being cancelled. Accordingly, this category can be considered as replacement or continuation of Options in existence at the last balance sheet date. Of the directors, Barry Mence has been granted 18,125 replacement Options, Andrew Michuda has been granted 49,000 and Arif Karimjee has been granted 26,875. Following this grant, Barry Mence has 24,250 Options in total, Andrew Michuda has 199,880 and Arif Karimjee has 57,500.

 

The Options granted will vest over 3 years, and are exercisable up to 10 years from the date of grant. The exercise price of the Options is 85 pence per share, being the mid-market closing price on AIM on 5 December 2013. Following this grant, the Company now has a total of 623,789 Options in issue, representing 8.6 per cent of the current issued share capital of the Company.

 

Chairman Barry Mence said: "This is the second such grant as we continue the process of improving the alignment of staff incentives with corporate goals, with new vesting conditions designed to encourage continued commitment to the Company."

 

In addition, Stuart Silcock is the executor and is a beneficiary of an estate that owns 500 Ordinary Shares. On 5 December 2013 these Ordinary Shares were transferred into his personal account for no consideration and are now held jointly for himself and the other beneficiary by way of declaration of trust. Following this transfer, Stuart Silcock's total shareholding is 52,000 Ordinary Shares, representing 0.7% per cent of the issued share capital of the Company. Stuart Silcock also holds £200,000 of convertible loan stock, which has a conversion price of £1 per Ordinary Share, and is a minority shareholder in Inkberrow Limited, a company which owns 115,500 Ordinary Shares.

 

For further information contact:

Barry Mence, Chairman

Sopheon plc

+ 44 (0) 1483 685 735

Arif Karimjee, CFO

Sopheon plc

+ 44 (0) 1483 685 735

Charlotte Stranner / Victoria Bates

finnCap

+ 44 (0) 20 7600 1658

Heather Armstrong

Newgate Threadneedle

+ 44 (0) 20 7653 9842

Claire Verhagen

Citigate First Financial

+ 31 (0) 205 754 010

 

About Sopheon

Sopheon (LSE: SPE) partners with customers to provide complete Enterprise Innovation Performance solutions including software, expertise, and best-practices to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade® solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle. For the first time, businesses can access a single source of the truth across strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on the AIM Market of the London Stock Exchange and on the Alternext Exchange in the Netherlands. For more information, please visit www.sopheon.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSKMMGZNKZGFZM
Date   Source Headline
27th Jan 20117:00 amPRNTrading Statement
9th Dec 20107:00 amPRNAmendment to the Terms of Convertible Loan Stock
16th Nov 20107:00 amPRNContract Win
4th Nov 20107:00 amPRNInterim Management Statement
27th Aug 201010:30 amPRNGrant of Options
26th Aug 20107:00 amPRNHalf-yearly Report
22nd Jul 20107:00 amRNSTrading Update
15th Jun 20105:31 pmPRNResult of AGM
15th Jun 20107:00 amPRNAGM Statement
18th May 20107:00 amRNSAfton Chemical Selects Idea Lab
6th May 20107:00 amPRNInterim Management Statement
25th Mar 20107:00 amPRNFinal Results
22nd Mar 20107:00 amRNSiSUSTAINT Alliance Launched
3rd Feb 20107:00 amRNSSopheon Team wins TARDEC Contract
28th Jan 20107:00 amPRNTrading Update
24th Dec 20097:01 amRNSExtension of GEM Equity Line
2nd Dec 20097:00 amRNSVision Strategist Version 5.0 Launched
3rd Nov 20097:00 amPRNInterim Management Statement
2nd Oct 20093:43 pmPRNISSUE OF CONVERTIBLE LOAN STOCK
27th Aug 20097:00 amPRNHalf-yearly Report
16th Jun 200912:34 pmPRNResult of AGM
16th Jun 20097:00 amPRNAGM Statement
19th May 20097:00 amPRNProduct Launch
7th May 20097:00 amPRNInterim Management Statement
26th Mar 20097:00 amPRNFinal Results
18th Mar 20097:00 amRNSBostik Implements Sopheon's Accolade System
11th Mar 20097:00 amRNSContract Win
11th Feb 20097:00 amRNSEnhanced Version of Accolade? Launched
28th Jan 20097:00 amPRNTrading Update
21st Jan 20097:00 amRNSSopheon Partners with Maxsoft
4th Nov 20087:00 amPRNInterim Management Statement
28th Aug 20087:00 amPRNHalf-yearly Report
27th Jun 20083:47 pmPRNDirector/PDMR Shareholding
25th Jun 20087:00 amPRNGrowth Milestone
10th Jun 20087:00 amPRNAGM Statement
16th May 20087:00 amPRNDirector/PDMR Shareholding
15th May 20087:00 amPRNInterim Management Statement
6th May 200810:00 amPRNNotice of AGM
29th Apr 20087:02 amRNSContract Win
1st Apr 200810:00 amPRNGrant of Options
27th Mar 20087:00 amPRNFinal Results
6th Feb 20087:01 amRNSProduct Development
25th Jan 20087:00 amPRNTrading Update
21st Dec 200710:30 amPRNTrading Update
25th Oct 20077:00 amPRNTrading Update
16th Oct 20072:38 pmBUSBeiersdorf Implements Sopheon System in Support of Product Innovation Strategy
16th Oct 20077:01 amRNSContract Win
10th Oct 20072:45 pmBUSLeading European Center for Clinical Trials Research Selects Sopheon's Accolade(R) System
10th Oct 20077:01 amRNSContract Win
1st Oct 20077:02 amRNSContract Win

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.